US29251M1062
© BusinessWire
08.01.2026
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs and highlighted upcoming key milestones for 2026.
“Building on the progress we achieved in our RSV and immun...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcar...
Themefolio
Profiler
Peergroup
© BusinessWire
17.11.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2025.
“This past quarter marked a pivotal period for Enanta, with significant pr...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
04.11.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December.
Jefferies London Global Healthcare Confer...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
20.10.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that new data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, its oral, once-daily L-protein inhibitor, both in development fo...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it’s oral, once-daily L-protein inhibitor, both in development for t...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that it has closed its previously announced underwritten public offering of 7,475,000 shares of its common stock, which includes 975,000 shares sold pursuant...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are b...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta i...
Themefolio
Profiler
Peergroup
© BusinessWire
29.09.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced positive topline data from RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of zelicapavir in outpat...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating z...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
“The entire Enanta team mourns the loss of Paul, our colleague and friend,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Since jo...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
21.08.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Participate in September Investor Conferences
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in three investor conferences in September:
Cantor Global Healthcare Conference 2025: Fireside Chat on Wednesda...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 3507...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, July 22 at 1:30 p.m. ET as part of Baird’s Biotech Discovery Series.
A li...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct acting an...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday,...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company’s Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster a...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2025.
“Throughout the fiscal second quarter, Enanta remained squarely focused on executing acr...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that data from the Company’s Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV) has been accepted for an oral...
Themefolio
Profiler
Peergroup
© BusinessWire
17.03.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will present at the at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
12.03.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three posters, including one late breaker, highlighting the company’s respiratory syncytial virus (RSV) program, will be presented at th...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024.
“2025 is primed to be a pivotal year for Enanta as we execute on multiple catalysts across ou...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 8:...
Themefolio
Profiler
Peergroup
© BusinessWire
24.12.2024
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2024
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from the first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months wit...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2024
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study e...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2024.
“Our fiscal fourth quarter was an exciting time for Enanta as we announced positiv...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). These data...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Participate in Investor Conferences in September
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will participate in three investor conferences being webcast in September:
Baird 2024 Global Healthcare Conference: Fireside Chat at 2:3...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
